These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 16199160)

  • 1. Preoperative (neoadjuvant) systemic treatment of breast cancer.
    Kaufmann M; von Minckwitz G; Rody A
    Breast; 2005 Dec; 14(6):576-81. PubMed ID: 16199160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary systemic therapy of breast cancer.
    Sachelarie I; Grossbard ML; Chadha M; Feldman S; Ghesani M; Blum RH
    Oncologist; 2006 Jun; 11(6):574-89. PubMed ID: 16794237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy].
    Straver ME; van Adrichem JC; Rutgers EJ; Rodenhuis S; Linn SC; Loo CE; Gilhuijs KG; Oldenburg HS; Wesseling J; Russell NS; Antonini N; Vrancken Peeters MT
    Ned Tijdschr Geneeskd; 2008 Nov; 152(46):2519-25. PubMed ID: 19055260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
    Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
    Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of radiation therapy on the use of primary ("neoadjuvant") systemic treatment of breast cancer].
    Souchon R; Dunst J; Hartmann KA
    Strahlenther Onkol; 2006 Apr; 182(4):202-9. PubMed ID: 16622621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preoperative tumor marker status.
    Piper GL; Patel NA; Patel JA; Malay MB; Julian TB
    Am Surg; 2004 Dec; 70(12):1103-6. PubMed ID: 15663054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy in breast cancer.
    Charfare H; Limongelli S; Purushotham AD
    Br J Surg; 2005 Jan; 92(1):14-23. PubMed ID: 15635596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant induction chemotherapy.
    Schwartz G
    Minerva Ginecol; 2005 Jun; 57(3):327-48. PubMed ID: 16166939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facilitating breast-conserving surgery and preventing recurrence: aromatase inhibitors in the neoadjuvant and adjuvant settings.
    Mamounas EP
    Ann Surg Oncol; 2008 Mar; 15(3):691-703. PubMed ID: 18196346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients.
    Garimella V; Qutob O; Fox JN; Long ED; Chaturvedi A; Turnbull LW; Drew PJ
    Eur J Surg Oncol; 2007 Mar; 33(2):157-61. PubMed ID: 17085007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effective treatment strategy in elderly breast cancer patients].
    Boér K
    Orv Hetil; 2005 Jan; 146(1):15-21. PubMed ID: 15715368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The surgical management of patients who achieve a complete pathological response after primary chemotherapy for locally advanced breast cancer.
    Clouth B; Chandrasekharan S; Inwang R; Smith S; Davidson N; Sauven P
    Eur J Surg Oncol; 2007 Oct; 33(8):961-6. PubMed ID: 17215100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.
    Gralow JR; Burstein HJ; Wood W; Hortobagyi GN; Gianni L; von Minckwitz G; Buzdar AU; Smith IE; Symmans WF; Singh B; Winer EP
    J Clin Oncol; 2008 Feb; 26(5):814-9. PubMed ID: 18258991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
    Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
    Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
    Taucher S; Steger GG; Jakesz R; Tausch C; Wette V; Schippinger W; Kwasny W; Reiner G; Greil R; Dubsky P; Poestlberger S; Tschmelitsch J; Samonigg H; Gnant M;
    Breast Cancer Res Treat; 2008 Nov; 112(2):309-16. PubMed ID: 18080748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of disseminated tumor cells in locally advanced breast cancer patients before primary systemic therapy.
    Solá M; Margelí M; Castellá E; Cirauqui B; Mariscal A; Rull M; Julian JF; Luna M; Vallejo V; Fraile M
    Breast; 2013 Oct; 22(5):908-13. PubMed ID: 23683695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
    Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Breast cancer].
    Kobayashi T; Yamazaki H; Nakamura T; Ogihara A; Fujii T; Hirano A; Uno S; Yoshida K; Nagata T; Uchida K; Kubo H; Tozaki M; Kanehira C; Miyazawa Y; Suzuki M; Kuraishi Y
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1814-25. PubMed ID: 11729473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
    Kaufmann M; Rody A
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.